We are live on ! Find out more
OIM

Oracle Investment Management Portfolio holdings

AUM $168M
1-Year Est. Return 42.86%
This Fund
S&P 500
This Quarter Est. Return
+22.37%
1 Year Est. Return
+42.86%
3 Year Est. Return
+864.89%
5 Year Est. Return
+1,153.35%
10 Year Est. Return
+22,228.86%
AUM
$430M
AUM Growth
+$45M
Cap. Flow
-$2.99M
Cap. Flow %
-0.7%
Top 10 Hldgs %
88.13%
Holding
20
New
–
Increased
3
Reduced
7
Closed
1

Top Buys

Rank Stock Value
1
PGEN icon
Precigen
PGEN
+$1.6M
2
TSRO
TESARO, Inc.
TSRO
+$1.16M
3
AXDX
Accelerate Diagnostics
AXDX
+$667K

Top Sells

Rank Stock Value
1
MZOR
Mazor Robotics Ltd.
MZOR
+$2M
2
YTEN
Yield10 Bioscience, Inc. Common Stock
YTEN
+$1.38M
3
PACB icon
Pacific Biosciences
PACB
+$1.19M
4
QDEL icon
QuidelOrtho
QDEL
+$692K
5
NXTM
NxStage Medical Inc.
NXTM
+$430K

Sector Composition

Rank Sector Weight
1 Healthcare 84.39%
2 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXDX
1
DELISTED
Accelerate Diagnostics
AXDX
$73.2M 17.04%
508,746
+4,971
+1% +$667K
NXTM
2
DELISTED
NxStage Medical Inc.
NXTM
$57.9M 13.48%
2,670,536
-24,100
-0.9% -$430K
TSRO
3
DELISTED
TESARO, Inc.
TSRO
$56.1M 13.05%
666,956
+25,990
+4% +$1.16M
MZOR
4
DELISTED
Mazor Robotics Ltd.
MZOR
$49.7M 11.58%
2,766,517
-143,049
-5% -$2M
QDEL icon
5
QuidelOrtho
QDEL
$1.21B
$45.2M 10.53%
2,533,554
-40,000
-2% -$692K
OPK icon
6
Opko Health
OPK
$978M
$36.6M 8.51%
3,914,000
– –
PACB icon
7
Pacific Biosciences
PACB
$441M
$22.4M 5.21%
3,182,269
-129,820
-4% -$1.19M
ARAY icon
8
Accuray
ARAY
$32.2M
$12.9M 3%
2,482,718
-70,500
-3% -$385K
BIOL
9
DELISTED
Biolase, Inc.
BIOL
$12.3M 2.87%
842
– –
AMRN
10
Amarin Corp
AMRN
$297M
$12.3M 2.86%
284,579
-6,361
-2% -$239K
HNSN
11
DELISTED
HANSEN MEDICAL, INC. COM NEW
HNSN
$11.7M 2.72%
4,491,820
– –
PGEN icon
12
Precigen
PGEN
$2.36B
$11.3M 2.63%
463,665
+56,302
+14% +$1.6M
VRML
13
DELISTED
Vermillion, Inc.
VRML
$9.57M 2.23%
8,624,225
– –
AGEN
14
Agenus
AGEN
$326M
$7.52M 1.75%
94,638
-1,274
-1% -$99.3K
TTHI
15
DELISTED
TRANSITION THERAPEUTICS INC (CANADA)
TTHI
$5.61M 1.31%
3,817,972
– –
CFRX
16
DELISTED
ContraFect Corporation
CFRX
$3.42M 0.8%
1,478
– –
BIIB icon
17
Biogen
BIIB
$29.8B
$1.63M 0.38%
6,723
– –
VANI icon
18
Vivani Medical
VANI
$115M
$182K 0.04%
2,117
– –
TCRT icon
19
Alaunos Therapeutics
TCRT
$4.66M
$37K 0.01%
44
– –
YTEN
20
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
– –
-76
Closed -$1.38M

Similar funds

BIO
Blue Investment Opportunities Miami Beach, Florida $168M AUM 21.32% 1-Year Est. Return
OBWA
Oak Barrel Wealth Advisory Reston, Virginia $167M AUM
EECFX
EnCap Energy Capital Fund XII Houston, Texas $169M AUM
PW
Pandora Wealth Oakbrook Terrace, Illinois $165M AUM 18.5% 1-Year Est. Return
PWA
Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return
AIMU
Allianz Investment Management US Minneapolis, Minnesota $160M AUM 4.75% 1-Year Est. Return
HIA
Harvest Investment Advisors Tallahassee, Florida $176M AUM
ACA
AG Campbell Advisory Baltimore, Maryland $158M AUM

Oracle Investment Management's Q2 2016 Portfolio in Review

As of Q2 2016, Oracle Investment Management held 20 positions worth $430M, up 12% from $385M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Oracle Investment Management's Q2 2016 filing shows 3 increased, 7 reduced and 1 closed positions. The largest sale was Mazor Robotics Ltd., an estimated $2M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 86% a quarter earlier, followed by Consumer Staples.

  • Oracle Investment Management added most to Precigen in Q2 2016, an estimated $1.6M increase.
  • Oracle Investment Management's biggest Q2 2016 reduction was Mazor Robotics Ltd., cutting an estimated $2M.
  • Oracle Investment Management fully exited Yield10 Bioscience, Inc. Common Stock in Q2 2016, selling an estimated $1.38M.
  • Oracle Investment Management's ten largest holdings make up 88% of its $430M portfolio in Q2 2016.
  • Oracle Investment Management opened 0 new positions and closed 1 in Q2 2016.
  • Oracle Investment Management's portfolio value rose 12% quarter-over-quarter to $430M.

Based on Oracle Investment Management's 13F filing for Q2 2016, filed 15 Aug 2016.